Market closedNon-fractional
MacroGenics/MGNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About MacroGenics
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
Ticker
MGNX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Rockville, United States
Employees
339
Website
www.macrogenics.com
MacroGenics Metrics
BasicAdvanced
$344M
Market cap
-
P/E ratio
-$0.38
EPS
2.08
Beta
-
Dividend rate
Price and volume
Market cap
$344M
Beta
2.08
Financial strength
Current ratio
3.633
Quick ratio
3.433
Long term debt to equity
28.192
Total debt to equity
32.04
Interest coverage (TTM)
-96.26%
Management effectiveness
Return on assets (TTM)
-38.77%
Return on equity (TTM)
-21.58%
Valuation
Price to revenue (TTM)
7.871
Price to book
3.22
Price to tangible book (TTM)
3.22
Price to free cash flow (TTM)
-2.997
Growth
Revenue change (TTM)
-73.78%
Earnings per share change (TTM)
-74.28%
3-year revenue growth (CAGR)
-26.25%
3-year earnings per share growth (CAGR)
-46.59%
What the Analysts think about MacroGenics
Analyst Ratings
Majority rating from 12 analysts.
MacroGenics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.1M
-14.95%
Net income
-$52M
13.26%
Profit margin
-572.52%
33.18%
MacroGenics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.92
$0.28
-$0.75
-$0.84
-
Expected
-$0.52
-$0.10
-$0.15
-$0.64
-$0.63
Surprise
-276.51%
-392.89%
387.96%
30.67%
-
MacroGenics News
AllArticlesVideos
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of MacroGenics, Inc. Securities and Sets a Lead Plaintiff Deadline of September 24, 2024
GlobeNewsWire·23 minutes ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by MacroGenics, Inc. (MGNX)
Accesswire·3 hours ago
The Schall Law Firm Is Investigating MacroGenics Inc And Urges Its Shareholders To Reach Out
Accesswire·3 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MacroGenics stock?
MacroGenics (MGNX) has a market cap of $344M as of July 27, 2024.
What is the P/E ratio for MacroGenics stock?
The price to earnings (P/E) ratio for MacroGenics (MGNX) stock is 0 as of July 27, 2024.
Does MacroGenics stock pay dividends?
No, MacroGenics (MGNX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next MacroGenics dividend payment date?
MacroGenics (MGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for MacroGenics?
MacroGenics (MGNX) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell MacroGenics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.